Collectively, these data provide strong evidence that Rig-I negatively regulates CD8+ T-cell function and that knocking out Rig-I enhances the differentiation, development, and anti-tumour activity of CD8+ T cells ex vivo. The gene discussed is CD8A; the disease is neoplasm.